Malignant Ovarian Germ Cell Tumours: A Survival and Prognostic Analysis

Ezzat, Adnan; Raja, M. A.; Bakri, Younis; Subhi, Jamal; Memon, Muhammad Yousuf; Schwartz, Peter E.; Stuart, Robert K.

doi:10.1080/028418699431988

Cited by 23 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this series, nearly 90% of patients had potentially fertility‐sparing surgery, out of which 54% went on to have successful pregnancies, including 5 of 11 (45%) patients who received relapse chemotherapy. In series published by Ezzat et al (28) and Zanagnolo et al (11) , the successful pregnancy rate in women undergoing fertility‐sparing surgery was 16 of 44 (36%) and 11 of 36 (31%), respectively. Perrin et al (29) demonstrated a pregnancy success rate of 7 of 29 (24%) in patients who had received chemotherapy and Bower et al (9) demonstrated a pregnancy rate of 14 of 33 (42%) following POMB/ACE chemotherapy, which are both comparable with our rate of 45%.…”

Section: Discussionmentioning

confidence: 95%

A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites

Patterson¹,

Murugaesu²,

Holden³

et al. 2008

International Journal of Gynecological Cancer

114

View full text Add to dashboard Cite

Ovarian germ cell tumors are rare but very curable at all stages of disease. There is good evidence that surveillance for stage I dysgerminomas is a safe option although many centers worldwide still advocate adjuvant chemotherapy for stage IA nondysgerminomatous tumors, despite the significant risk of developing long-term treatment side effects. Here, we review the safety of our ongoing surveillance program of all stage IA female germ cell tumors. Thirty-seven patients (median age 26, range 14-48 years) with stage I disease were referred to Mount Vernon and Charing Cross Hospitals between 1981 and 2003. Patients underwent surgery and staging followed by intense surveillance, which included regular tumor markers and imaging. The median period of follow-up was 6 years. Relapse rates for stage IA nondysgerminomatous tumors and dysgerminomas were 8 of 22 (36%) and 2 of 9 (22%), respectively, plus one patient with mature teratoma and glial implants also relapsed; 10 of these 11 patients (91%) were successfully cured with platinum-based chemotherapy. Only one patient died from chemoresistant disease. All relapses occurred within 13 months of initial surgery. The overall disease-specific survival of malignant ovarian germ cell tumors was 94%. Over 50% of patients who underwent fertility-sparing surgery went on to have successful pregnancies. We have confirmed again that surveillance of all stage IA ovarian germ cell tumors is very safe and that the outcome is comparable with testicular tumors. We question the need for potentially toxic adjuvant chemotherapy in nondysgerminoma patients who have greater than 90% chance of being salvaged with chemotherapy if they relapse later.

show abstract

Section: Discussionmentioning

confidence: 95%

A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites

Patterson¹,

Murugaesu²,

Holden³

et al. 2008

International Journal of Gynecological Cancer

114

View full text Add to dashboard Cite

show abstract

“…AFP is present in high levels in tumors arising from endodermal sinus, while b-hCG is present in tumors such as embryonal carcinoma, choriocarcinoma and teratoma. Therefore, determination of serum AFP level is considered a useful diagnostic tool in the patient affected with yolk sac tumor [3,4], to monitor the results of therapy and also to identify relapses and metastasis during the follow-up [5].…”

Section: Resultsmentioning

confidence: 99%

Yolk sac tumor in a young girl: A case report

Razzi

Luisi

Gabbanini

et al. 2005

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…Literature has reported several healthy babies born after fertilitysparing surgery with or without chemotherapy for MOGCT [7,8,15,17,[30][31][32][34][35][36][37][38][39][40][41][42] (Table 2).…”

Section: Obstetric Outcomementioning

confidence: 97%

“…After cancer treatment, seven survivors had miscarriages and four had terminations. [8] MOGCT 74y 16 healthy babies Zanetta [15] MOGCT 128y 38 healthy babies 2 babies with malformations 9 miscarriages 6 terminations (2 for malformations) Weinberg [17] MOGCT 10y 14 living babies (3 with assisted reproductive technologies) Al Husaini [30] DYS 50y 14 living babies Gershenson [31] MOGCT 62* 37 healthy babies 7 miscarriages 4 terminations Curtin [32] MOGCT 27y 4 healthy babies Kang [34] EST 15* 2 healthy babies De La Motte Rouge [35] EST 40* 15 healthy babies 1 ongoing pregnancy 2 miscarriages 1 termination Bower [36] MOGCT 33* 14 healthy babies Ezzat [37] MOGCT 44y 16 healthy babies Kanazawa [38] MOGCT 20y 9 healthy babies Vicus [39] DYS 50y 12 living babies Tangir [40] MOGCT 64y 38 babies (no congenital anomalies in the 16 babies for whom follow-up data were available) 2 miscarriages 10 terminations *All had adjuvant chemotherapy; ysome of them had adjuvant chemotherapy. DYS, dysgeminoma; MOCGT, malignant ovarian germ cell tumor; EST, endodermal sinus tumor.…”

Section: Obstetric Outcomementioning

confidence: 98%

Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours

Gadducci

Lanfredini

Tana

2014

Gynecological Endocrinology

View full text Add to dashboard Cite

Malignant ovarian germ cell tumours (MOGCT) account for 5% of all ovarian malignancies. Their elevated chemosensitivity, the frequent unilaterality and the young age of patients have strongly supported the conservative surgery as the standard approach, often followed by adjuvant platinum-based chemotherapy. The risk for recurrence is not affected by the performance of conservative versus radical surgery. During chemotherapy 50% of patients become amenorrhoeic but more than 95% of them resume normal menses after treatment completion. Literature has reported several healthy babies born after fertility-sparing surgery with or without chemotherapy for MOGCT. The incidence of miscarriages is in the normal range, whereas malformation rate is slightly higher compared to general population, without any difference between chemotherapy-treated and -untreated patients. Therefore, young women with MOGCT must be reassured of their excellent chances of survival and fertility preservation following conservative surgery and adjuvant platinum-based chemotherapy.

show abstract

Malignant Ovarian Germ Cell Tumours: A Survival and Prognostic Analysis

Cited by 23 publications

References 16 publications

A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites

A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites

Yolk sac tumor in a young girl: A case report

Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours

Contact Info

Product

Resources

About